Welcome to our dedicated page for NeOnc Technologies Holdings news (Ticker: NTHI), a resource for investors and traders seeking the latest updates and insights on NeOnc Technologies Holdings stock.
NeOnc Technologies Holdings, Inc. (NTHI) is a clinical-stage biotechnology leader focused on central nervous system therapeutics and advanced drug delivery systems. This page provides investors and industry observers with timely updates on clinical trial progress, regulatory developments, and strategic initiatives critical to evaluating the company's position in the CNS treatment market.
Access consolidated information on NTHI's proprietary NEO platform advancements, intellectual property milestones, and collaborative research partnerships. The resource covers essential updates including FDA designations, trial phase results, and executive commentary without speculative analysis.
Key content types include earnings communications, clinical trial status reports, patent filings, and leadership updates. All materials maintain compliance with financial disclosure regulations while emphasizing technological developments in blood-brain barrier penetration techniques.
Bookmark this page for streamlined tracking of NTHI's progress in addressing complex neurological conditions through its innovative therapeutic pipeline. Regular updates ensure stakeholders remain informed about developments that may influence long-term research trajectories and market positioning.
NeOnc Technologies (NASDAQ: NTHI) announced on November 4, 2025 that Amir Heshmatpour has been appointed Chief Executive Officer, effective immediately, while continuing as Executive Chairman.
Founder Dr. Thomas Chen will transition from CEO to focus on Chief Medical Officer and Chief Scientific Officer roles and clinical development of the company’s multi-Phase 2 programs. Recent corporate milestones cited include a $50 million strategic partnership with Quazar Investment, establishment of a UAE subsidiary (NuroMENA), expansion of the Scientific Advisory Board, and a NEO™ platform protected by more than 179 worldwide patents.
NeOnc Technologies (NASDAQ:NTHI) announced that His Highness Sheikh Nahyan bin Zayed Al Nahyan will formally assume the role of Executive Chairman of NuroMENA, NeOnc's Middle East subsidiary, effective Oct. 28, 2025. Amir Heshmatpour will transition to Vice Chairman of NuroMENA. The move establishes a UAE–US partnership focused on advancing therapies for brain cancer and other CNS malignancies.
The release highlights expected strategic support from the influence and resources of a major sovereign wealth fund and frames the appointment as strengthening humanitarian and innovation efforts to accelerate development of NeOnc’s multi‑Phase 2 clinical programs.
NeOnc Technologies (NASDAQ: NTHI) announced that its wholly owned subsidiary NuroMENA signed a Master Services Agreement (MSA) with UAE-based contract research organization IROS, part of the M42 group, to support clinical development in the Middle East on October 9, 2025. The MSA grants NuroMENA access to Abu Dhabi’s health ecosystem, AI/technology and genomics capabilities to accelerate NeOnc’s Phase 2 CNS cancer programs.
Concurrently, NuroMENA expanded its board to add two Quazar Investment representatives, including CEO Waleed K. Al Ali and the Quazar chairman, joining existing directors Amir Heshmatpour, Dr. Ishwar K. Puri and Bader Al Monawer to oversee regional strategy.
NeOnc Technologies (NASDAQ:NTHI) announced that, after receiving required UAE tax and regulatory approvals, a previously signed definitive agreement with Abu Dhabi-based Quazar Investment for a $50 million strategic equity partnership is mandated to close no later than October 23, 2025. The deal centers on Abu Dhabi operating subsidiary NuroCure under NuroMENA Holdings, which was incorporated in the Abu Dhabi Global Market on August 6, 2025, satisfying closing contingencies. The partnership allocates $15 million specifically to Phase 2B clinical trials and UAE/MENA infrastructure development and aims to accelerate NeOnc’s pipeline, including NEO100 (multiple trials) and NEO212 programs, plus a pediatric NEO100-03 Phase 1 trial, in collaboration with Cleveland Clinic UAE.
NeOnc Technologies (NTHI), a clinical-stage biopharmaceutical company focused on CNS cancer therapies, has appointed Dr. David M. Ashley to its Scientific Advisory Board. Dr. Ashley serves as the Director of The Preston Robert Tisch Brain Tumor Center at Duke University and holds the position of Rory David Deutsch Distinguished Professor of Neuro-Oncology.
Dr. Ashley brings significant expertise in brain tumor immunology and epigenetics, with experience in both pediatric and adult brain cancers. His appointment is expected to strengthen NeOnc's pipeline, particularly the development of lead candidates NEO100™ and NEO212™. Since 2018, he has led one of North America's largest dedicated brain tumor centers, integrating clinical care, translational research, and education.
NeOnc Technologies (NTHI), a clinical-stage biopharmaceutical company focused on central nervous system (CNS) cancers, has appointed Dr. Alexandra M. Miller to its Scientific Advisory Board. Dr. Miller serves as Chief of Neuro-Oncology and Co-Director of the Brain and Spine Tumor Center at NYU Langone Health's Perlmutter Cancer Center.
Dr. Miller's expertise in liquid biopsy assays for CNS tumors and cerebrospinal fluid diagnostics will support NeOnc's clinical trials for NEO100™ and NEO212™. The appointment coincides with NeOnc's expansion of its global trial network into the Middle East and India, strengthening the company's position in brain cancer research.
NeOnc Technologies (NTHI), a clinical-stage biopharmaceutical company focused on CNS cancer therapies, has appointed Dr. Henry S. Friedman to its scientific advisory board. Dr. Friedman, a distinguished neuro-oncologist from Duke University's Preston Robert Tisch Brain Tumor Center, brings extensive expertise with over 500 peer-reviewed publications.
As a deputy director at the Brain Tumor Center and holder of the James B. Powell, Jr. Distinguished Professorship, Dr. Friedman's appointment comes at a crucial time as NeOnc prepares to publish data from its NEO100™ and NEO212™ clinical programs. His expertise will be instrumental in reviewing and validating these upcoming results, particularly in the areas of glioblastoma and other brain cancers.
NeOnc Technologies (NASDAQ:NTHI), a clinical-stage biotech company, will be featured on "Health Uncensored with Dr. Drew" on the Lifetime Network, reaching approximately 63 million TV households on September 25th at 8:00 a.m. ET/PT.
The company has achieved several key milestones, including a $50 million strategic partnership with Quazar Investment, FDA authorization for Phase II trials of NEO212, and $2.5 million in NIH grants. NeOnc's NEO™ platform technology focuses on delivering therapies across the Blood-Brain Barrier to treat brain cancer, with two drug candidates (NEO100™ and NEO212™) currently in clinical trials under FDA Fast-Track status.
NeOnc Technologies (NASDAQ: NTHI) has received FDA authorization to proceed with Phase IIa/IIb clinical trial of NEO212, its first-in-class oral chemical conjugated chemotherapy for brain cancer. The approval follows successful Phase I completion, which demonstrated safe administration at doses up to 810 mg daily on Days 1-5 of a 28-day cycle.
NEO212 combines Temozolomide (TMZ), the current standard treatment for glioblastoma, with NEO100, NeOnc's proprietary form of perillyl alcohol. The drug aims to overcome TMZ's limitations by enhancing blood-brain barrier penetration and antitumor activity. Patient enrollment is expected to begin by end of 2025, expanding from 4 current trial sites to multiple premier cancer institutions across the U.S.
NeOnc Technologies (NASDAQ:NTHI) has completed the acquisition of a strategic intellectual property portfolio focused on AI, 3D bioprinting, and quantum modeling technologies for $3.5 million ($500,000 cash and $3 million in stock at $25/share). The acquired technology, including U.S. Patent No. 11,788,057 B2, enables the creation of sophisticated patient-derived 3D brain tumor models.
The acquisition enhances NeOnc's drug discovery capabilities by combining AI and quantum modeling algorithms with realistic biological environments for more efficient therapeutic candidate screening. Alongside this development, the company appointed Dr. Ishwar K. Puri, Senior Vice President of Research and Innovation at USC and a globally recognized scholar, to its Board of Directors.
FAQ
What is the current stock price of NeOnc Technologies Holdings (NTHI)?
What is the market cap of NeOnc Technologies Holdings (NTHI)?
